Company intelligence / Profile preview
Eloxx Pharmaceuticals
Watertown, Massachusetts, United Stateseloxxpharma.com ↗
- Ownership
- Public · ELOX
- Employees
- ~18
- Development stage
- Phase 2
01
Overview
Eloxx Pharmaceuticals has demonstrated proof-of-concept clinical activity with its lead candidate ELX‑02 in patients with nonsense mutation Alport Syndrome and cystic fibrosis. The company’s pipeline includes additional preclinical programs targeting rare genetic diseases caused by premature stop codons. Its proprietary platforms are designed to restore protein production by enabling read-through of premature stop codons or modulating ribosomes. Recent data from a proof-of-concept trial in nonsense mutation Alport Syndrome were presented at a late-breaking session in November 2024.
- Therapeutic areas
- GastroenterologyRare DiseasesDermatologyNephrology
- Modalities
- Small molecules (specifically eukaryotic ribosomal selective glycosides/ERSGs)RNA-modulating agents
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Financials
- Market cap
- $55.9M
- Total revenue
- $0
- Enterprise value
- $-6M
Beyond the preview
Go deeper on Eloxx Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Eloxx Pharmaceuticals.